Luspatercept
Also known as: ACE-536, ACE‑536, Luspatercept, luspatercept-aamt, Reblozyl
Source Luspatercept at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Luspatercept is a recombinant fusion protein approved for the treatment of anemia in adults with lower‑risk myelodysplastic syndromes (MDS) that have ring sideroblasts and are dependent on red‑cell transfusions. By trapping select ligands of the transforming growth factor‑β (TGF‑β) superfamily, it promotes late‑stage erythroid maturation, reducing transfusion requirements and raising hemoglobin levels.
Mechanism of Action
Luspatercept consists of the extracellular domain of the activin receptor type IIB fused to a human IgG1 Fc fragment. The molecule binds multiple TGF‑β superfamily ligands, notably activins and growth‑differentiation‑factor 11, preventing them from activating the SMAD2/3 signaling cascade in erythroid progenitors. Inhibition of SMAD2/3 releases the block on late‑stage erythroid differentiation, allowing maturation of red‑cell precursors and increased hemoglobin production.
What the Research Shows
Phase 3, double‑blind, placebo‑controlled trials in ESA‑refractory, transfusion‑dependent lower‑risk MDS with ring sideroblasts demonstrated that luspatercept achieved transfusion independence for ≥8 weeks in 38% of patients versus 13% with placebo (NEJM 2020). An interim analysis of the open‑label COMMANDS trial compared luspatercept to epoetin alfa in ESA‑naïve patients, showing a 59% response rate versus 31% for epoetin alfa, with longer median exposure (Lancet 2023). Reviews note that luspatercept is approved for lower‑risk disease, while higher‑risk MDS still relies on hypomethylating agents, and combination regimens have not shown added benefit. Safety data across studies indicate a generally tolerable profile, with the most common adverse events being fatigue, nausea, and hypertension.
Reported Benefits
Clinical trials have shown that luspatercept can substantially increase the proportion of lower‑risk MDS patients who become transfusion independent, improve hemoglobin levels, and reduce overall transfusion burden. The drug offers an alternative to erythropoiesis‑stimulating agents, especially in patients who are ESA‑refractory or have discontinued ESA due to side effects. Improved quality of life and reduced transfusion‑related complications are reported benefits in the studied populations.
Limitations of the Evidence
Evidence is confined to lower‑risk MDS with ring sideroblasts; data for higher‑risk MDS are lacking and the drug is not approved for that setting. Long‑term outcomes, including overall survival and progression to acute leukemia, remain uncertain. The COMMANDS comparison with epoetin alfa is based on an interim analysis, and definitive conclusions await final results. Combination strategies with other agents have not demonstrated superior efficacy to monotherapy.
Safety Considerations
The most frequently reported adverse events include fatigue, asthenia, nausea, dizziness, and hypertension; grade 3–4 events such as hypertension, neutropenia, thrombocytopenia, and pneumonia have also been observed. A case of acute myeloid leukemia was deemed possibly related to treatment. Overall, the safety profile is considered manageable, but clinicians should monitor blood pressure, infection signs, and hematologic parameters during therapy.
How It Is Administered
Luspatercept is administered by subcutaneous injection every three weeks. The starting dose is 1.0 mg/kg, with possible titration up to 1.75 mg/kg based on response and tolerability. The formulation is a protein‑based fusion product supplied in a sterile solution for injection.
Routes of Administration
Goals & Uses
- Treatment of anemia in lower-risk MDS (non-RS)Hematologic / InvestigationalModerate
- Reduction of transfusion burden in beta-thalassemiaHematologic / Anemia ManagementHigh
- Reduce transfusion burden in β‑thalassemiaHematologyHigh
- Improve anemia in lower‑risk MDS with ring sideroblastsHematologyHigh
- Treatment of anemia in MDS with ring sideroblastsHematologic / Anemia ManagementHigh
- Improvement of erythropoiesis in myelofibrosis-associated anemiaHematologic / InvestigationalModerate
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to luspatercept or any component of the formulationAllergyHigh
- Known hypersensitivity to luspatercept or excipientsAllergyHigh
Adverse Effects
- Bone painMusculoskeletalCommon
- HypertensionCardiovascularCommonHigh blood pressure
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularUncommon
- Musculoskeletal pain (bone pain, arthralgia, myalgia)MusculoskeletalCommon
- FatigueGeneralCommonLow energy or tiredness
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Erythropoiesis-stimulating agents (ESAs)Moderate
- Antihypertensive agentsLow
- Erythropoiesis‑stimulating agents (ESAs)Moderate
Population Constraints
- Pediatric patients (<18 years)AgeRelative
- Pediatric patientsAgeRelative
- Patients with uncontrolled hypertensionCardiovascularAbsolute
- Patients with severe hepatic impairmentHepaticRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
- Splenectomized patientsSurgical HistoryRelative
Regulatory Status
- European UnionApprovedApproved: Transfusion‑dependent β‑thalassemia, Lower‑risk MDS with ring sideroblastsMarketing authorisation granted in 2021.
- United StatesApprovedApproved: Transfusion‑dependent β‑thalassemia, Lower‑risk myelodysplastic syndromes with ring sideroblastsPrescribed under brand name Reblozyl.
- United KingdomApprovedApproved: Anemia in adults with transfusion-dependent beta-thalassemia, Anemia in adults with MDS with ring sideroblastsMHRA approved; NICE technology appraisals have evaluated use in MDS and beta-thalassemia with conditional recommendations
FDA approved (2020 for transfusion‑dependent β‑thalassemia; 2023 for MDS with ring sideroblasts). EMA approval for same indications in 2021.
Evidence & Sources
- Journal ArticleModerateKröger N2025-01-01T00:00:00.000000Z
- Journal ArticleModeratePlatzbecker U, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateFenaux P, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateGarcia-Manero G2023-01-01T00:00:00.000000Z
- Journal ArticleModeratePassamonti F, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of myelodysplastic syndrome patients are eligible for luspatercept?
Luspatercept is approved for adults with lower‑risk MDS (very low, low, or intermediate) that have ring sideroblasts and are dependent on red‑cell transfusions, particularly when erythropoiesis‑stimulating agents have failed or are unsuitable.
How does luspatercept differ from traditional erythropoietin therapy?
Unlike erythropoietin, which stimulates early erythroid progenitors via the EPO receptor, luspatercept blocks TGF‑β ligands that inhibit late‑stage erythroid maturation, thereby promoting the final steps of red‑cell development and reducing transfusion needs.
What are the most common side effects patients should expect?
Patients most often report fatigue, nausea, dizziness, and mild hypertension. Laboratory monitoring may reveal transient neutropenia or thrombocytopenia, and clinicians should watch for infections such as pneumonia.
Is luspatercept used for higher‑risk MDS or other blood disorders?
Current evidence and regulatory approvals limit luspatercept to lower‑risk MDS with ring sideroblasts. Studies in higher‑risk disease or other conditions, such as myelofibrosis, are ongoing but have not yet demonstrated efficacy.
How long does treatment typically continue?
Treatment is continued as long as the patient derives clinical benefit and tolerates the medication, with dosing every three weeks. Ongoing assessment of transfusion needs, hemoglobin levels, and adverse events guides continuation.
What is Luspatercept?
Luspatercept is a recombinant fusion protein approved for the treatment of anemia in adults with lower‑risk myelodysplastic syndromes (MDS) that have ring sideroblasts and are dependent on red‑cell transfusions. By trapping select ligands of the transforming growth factor‑β (TGF‑β) superfamily, it promotes late‑stage erythroid maturation, reducing transfusion requirements and raising hemoglobin levels.
What is Luspatercept used for?
Luspatercept is educationally associated with: Treatment of anemia in lower-risk MDS (non-RS), Reduction of transfusion burden in beta-thalassemia, Reduce transfusion burden in β‑thalassemia, Improve anemia in lower‑risk MDS with ring sideroblasts, Treatment of anemia in MDS with ring sideroblasts, Improvement of erythropoiesis in myelofibrosis-associated anemia. Educational only — not medical advice.
How is Luspatercept administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Luspatercept?
Reported adverse effects include: Bone pain, Hypertension, Headache, Thromboembolic events, Musculoskeletal pain (bone pain, arthralgia, myalgia), Fatigue, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Luspatercept?
Recorded contraindications: Pregnancy, Hypersensitivity to luspatercept or any component of the formulation, Known hypersensitivity to luspatercept or excipients. Consult a qualified clinician before use.